IP Library Granted Patent US 11,980,649
Granted Patent B2
US 11,980,649 · App. 17/257,529 · Granted May 14, 2024

Composition for the prevention or treatment of respiratory diseases caused by fine dust comprising

Inventors: Jeong Ho Geum (Seoul, KR); Hye Rim Kim (Seoul, KR); Jin Hak Kim (Seoul, KR); Su Young Choi (Seoul, KR)
Assignees: Cosmax NBT, Inc.; Cosmax NS. Inc.
A61K36/532A23L33/105A61K36/484
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,980,649
App. No.
17/257,529
Granted
May 14, 2024
Kind
B2
Abstract

The Agastache rugosa and licorice complex mixture of the present invention has the synergy effects for the efficacies of reducing cough through inhibition of TRPV1 activity, reducing lung inflammation through inhibition of CXCR1 and CXCR2 activities and GR-1+CD11b+ cell ratio reduction, and suppressing sputum production through inhibition of MUC5AC activity and therefore it can be widely utilized as a composition for the prevention or treatment of respiratory diseases.

Claims (3)

1. A method for preventing, ameliorating or treating a respiratory disease, comprising administering a composition consisting of an Agastache rugosa extract and a licorice extract to a subject in need thereof at an effective amount, wherein the respiratory disease is induced by inhalation of fine dust and is one or more selected from the group consisting of respiratory inflammatory pulmonary disease, chronic obstructive pulmonary disease (COPD), sinusitis, allergic rhinitis, lower respiratory tract infection, acute and chronic bronchitis, emphysema, pneumonia, bronchial asthma, bronchiectasis, emphysema, pulmonary tuberculosis sequelae, acute respiratory distress syndrome, and pulmonary fibrosis.

2. The method of claim 1 , wherein the Agastache rugosa extract and the licorice extract are mixed with Agastache rugosa and licorice at a weight ratio of 1:1 to 6:1.

3. The method of claim 1 , wherein the Agastache rugosa extract and the licorice extract reduce cough through inhibition of TRPV1 activity, reduce lung inflammation through inhibition of CXCR1 or CXCR2 activity, or GR-1+CD11b+ cell ratio reduction, and suppress sputum production through inhibition of MUC5AC activity.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2026
From: COSMAX NS, INC.
To: COSMAX NBT, INC.
Reel/Frame 074834/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: GEUM, JEONG HO; CHOI, SU YOUNG
To: COSMAX NBT, INC.
Reel/Frame 054926/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2021
From: KIM, JIN HAK; KIM, HYE RIM
To: COSMAX NS, INC.
Reel/Frame 054926/0697 →
Priority Claims (1)
KR 10-2020-0020369 · Feb 19, 2020 · national
Continuity (1)
Related Publication 20230210932A1 · Jul 6, 2023